Lilly pulls an obesity trial — plus, Amazon's $2.5B FTC settlement and Meta-TikTok implications

Markets are experiencing broad declines, with speculative and AI-related stocks, including Oracle following an $18 billion bond sale for AI capex, under pressure. The healthcare sector is also down amid a new Trump administration tariff investigation into medical devices. Eli Lilly terminated a mid-stage trial for its bimagrumab muscle-preserving therapy combined with GLP-1 tirzepatide for "strategic business reasons," raising concerns about the commercial prospects of such combination therapies and causing a ~3% stock decline. Separately, Amazon settled with the FTC for $2.5 billion over Prime cancellation processes, a resolution initially viewed positively by investors, while an expected deal for TikTok to continue U.S. operations removes a potential upside catalyst for Meta Platforms.

Analysis

The market is exhibiting a risk-off sentiment, evidenced by the S&P 500's third consecutive session of declines and pronounced selling pressure on unprofitable speculative stocks and AI-related equities. This trend is underscored by concerns over the capital intensity of the AI buildout, highlighted by Oracle's turn to the bond market with an $18 billion debt sale to fund its AI capital expenditures, as its cash flow is no longer sufficient. Simultaneously, the healthcare sector is underperforming due to a newly opened "Section 232" tariff investigation into medical devices, creating a sector-wide overhang despite some analysts anticipating minimal tangible impact. Within biotech, Eli Lilly's stock dropped approximately 3% after it terminated a mid-stage trial for its muscle-preserving therapy, bimagrumab, combined with its GLP-1 drug tirzepatide. The company cited "strategic business reasons" rather than safety concerns, but the move adds uncertainty to the commercial prospects of GLP-1 combination therapies, leading analysts at Jefferies to exclude bimagrumab from their financial models. On the regulatory front, Amazon reached a $2.5 billion settlement with the FTC over its Prime cancellation process; the stock's initial positive reaction suggests investor relief at the removal of this overhang. Lastly, the expected deal allowing TikTok to continue its U.S. operations removes a potential bull-case catalyst for Meta Platforms, which was predicated on a ban shifting users and ad revenue.

Key Decisions for Investors

• Investors in Eli Lilly should temper near-term expectations for its muscle-preserving combination therapies and refocus on the clinical and regulatory progress of its oral GLP-1, orforglipron, as the more critical value driver.
• Given the pressure on AI stocks and Oracle's significant debt issuance for capex, it is prudent to scrutinize the balance sheets and free cash flow of companies in the AI infrastructure space to assess their ability to fund ambitious growth projects.
• The tariff-induced weakness in the healthcare sector could offer a tactical entry point into fundamentally sound companies like Danaher, but investors must weigh this against the new, unquantified geopolitical risk overhang.
• The market's positive initial reaction to Amazon's expensive settlement highlights the value of regulatory clarity; therefore, monitor upcoming regulatory catalysts for other mega-cap tech firms as resolutions can unlock value by removing uncertainty.